ZYUS — Zyus Life Sciences Income Statement
0.000.00%
- CA$56.51m
- CA$64.11m
- CA$0.35m
Annual income statement for Zyus Life Sciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0.298 | 0.351 |
Cost of Revenue | |||||
Gross Profit | -0.017 | 0.001 | -0.028 | -0.232 | 0.171 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.398 | 0.205 | 0.228 | 19.1 | 44.5 |
Operating Profit | -0.397 | -0.204 | -0.228 | -18.8 | -44.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.274 | -0.728 | 0.351 | -24.7 | -48.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.274 | -0.728 | 0.351 | -24.7 | -42.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.274 | -0.728 | 0.351 | -24.7 | -42.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.274 | -0.728 | 0.351 | -24.7 | -42.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.055 | -0.145 | 0.07 | -0.599 | -0.447 |